Celldex Therapeutics Quarterly Cash Flow Statement
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Celldex Therapeutics generated -$57.4 million of operating cash flow and spent $3.2 million on capital expenditures. That left free cash flow of -$60.6 million, a free-cash-flow margin of -275404.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -73.50M | -78.69M | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M | -38.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 902.00K | 854.00K | 816.00K | 824.00K | 873.00K | 867.00K | 819.00K | 786.00K | 797.00K | 775.00K | 759.00K | 767.00K |
| Stock-Based Compensation | 8.41M | 8.52M | 8.91M | 8.80M | 9.19M | 9.32M | 9.78M | 9.62M | 7.64M | 7.20M | 7.21M | 7.12M |
| Change in Working Capital | 9.65M | -1.94M | 63.00K | 12.59M | 3.05M | -10.35M | 7.30M | -9.65M | 2.82M | -12.50M | 838.00K | 11.19M |
| Operating Cash Flow | -57.41M | -65.59M | -63.94M | -48.63M | -44.01M | -54.37M | -32.48M | -55.34M | -29.33M | -40.64M | -32.53M | -18.99M |
| Capital Expenditures | -3.18M | -1.64M | -1.28M | -440.00K | -728.00K | -265.00K | -756.00K | -545.00K | -274.00K | -344.00K | -666.00K | -157.00K |
| Investing Cash Flow | -255.52M | 72.12M | 55.42M | 60.85M | 49.85M | 42.95M | 24.05M | 47.76M | -46.72M | -315.21M | -171.16M | 11.65M |
| Financing Cash Flow | 324.66M | 327.00K | 1.35M | 774.00K | 63.00K | 202.00K | 386.00K | 1.24M | 3.71M | 436.11M | 217.37M | 257.00K |
| Net Change in Cash | 11.72M | 6.86M | -7.17M | 12.99M | 5.91M | -11.22M | -8.04M | -6.34M | -72.34M | 80.26M | 13.68M | -7.09M |
| Free Cash Flow | -60.59M | -67.23M | -65.22M | -49.07M | -44.73M | -54.64M | -33.23M | -55.88M | -29.60M | -40.98M | -33.20M | -19.15M |
This table shows 12 quarterly periods of Celldex Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a cash flow statement?